{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:42:21Z","timestamp":1790962941493,"version":"4.1.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-39629-7","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:52:42Z","timestamp":1770976362000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Molecular docking and dynamics reveal novel CDK6 inhibitors for targeted glioblastoma therapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Muhammad Umer","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina","family":"Manzoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Hamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir Ali","family":"Chohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badriyah S.","family":"Alotaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"39629_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s11060-016-2318-3","volume":"131","author":"A Darlix","year":"2017","unstructured":"Darlix, A. et al. Epidemiology for primary brain tumors: a nationwide population-based study. J. Neurooncol.. 131, 525\u2013546 (2017).","journal-title":"J. Neurooncol"},{"key":"39629_CR2","first-page":"7","volume":"54","author":"T Tykocki","year":"2018","unstructured":"Tykocki, T. & Eltayeb, M. Ten-year survival in glioblastoma. A systematic review. J. Clin. Neurosci. Off J. Neurosurg. Soc. Australas. 54, 7\u201313 (2018).","journal-title":"J. Clin. Neurosci. Off J. Neurosurg. Soc. Australas"},{"key":"39629_CR3","doi-asserted-by":"crossref","unstructured":"Pouyan, A. et al. Role of LncRNAs in brain tumors. Gene Rep. 101904 (2024).","DOI":"10.1016\/j.genrep.2024.101904"},{"key":"39629_CR4","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united States in 2015\u20132019. Neuro Oncol. 24, v1\u2013v95 (2022).","journal-title":"Neuro Oncol."},{"key":"39629_CR5","first-page":"299","volume":"70","author":"AC Tan","year":"2020","unstructured":"Tan, A. C. et al. Management of glioblastoma: state of the Art and future directions. CA Cancer J. Clin. 70, 299\u2013312 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"39629_CR6","doi-asserted-by":"crossref","unstructured":"Grochans, S. et al. Epidemiology of glioblastoma Multiforme-Literature review. Cancers (Basel) 14, (2022).","DOI":"10.3390\/cancers14102412"},{"key":"39629_CR7","doi-asserted-by":"crossref","unstructured":"Khabibov, M. et al. Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review). Int. J. Oncol. 60, (2022).","DOI":"10.3892\/ijo.2022.5359"},{"key":"39629_CR8","doi-asserted-by":"crossref","unstructured":"Tamimi, A. F. & Juweid, M. Epidemiology and outcome of glioblastoma. Exon Publ 143\u2013153 (2017).","DOI":"10.15586\/codon.glioblastoma.2017.ch8"},{"key":"39629_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40268-017-0180-1","volume":"17","author":"D Lubanska","year":"2017","unstructured":"Lubanska, D. & Porter, L. Revisiting CDK inhibitors for treatment of glioblastoma multiforme. Drugs R D. 17, 255\u2013263 (2017).","journal-title":"Drugs R D"},{"key":"39629_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.tcb.2021.01.010","volume":"31","author":"M Bury","year":"2021","unstructured":"Bury, M., Le Calv\u00e9, B., Ferbeyre, G., Blank, V. & Lessard, F. New insights into CDK regulators: novel opportunities for cancer therapy. Trends Cell. Biol. 31, 331\u2013344 (2021).","journal-title":"Trends Cell. Biol."},{"key":"39629_CR11","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan, C. W. et al. The somatic genomic landscape of glioblastoma. Cell 155, 462\u2013477 (2013).","journal-title":"Cell"},{"key":"39629_CR12","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41582-019-0220-2","volume":"15","author":"AM Molinaro","year":"2019","unstructured":"Molinaro, A. M., Taylor, J. W., Wiencke, J. K. & Wrensch, M. R. Genetic and molecular epidemiology of adult diffuse glioma. Nat. Rev. Neurol. 15, 405\u2013417 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"39629_CR13","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-17-0803","volume":"23","author":"I Olmez","year":"2017","unstructured":"Olmez, I. et al. Combined CDK4\/6 and mTOR Inhibition is synergistic against glioblastoma via multiple mechanisms. Clin. Cancer Res. 23, 6958\u20136968 (2017).","journal-title":"Clin. Cancer Res."},{"key":"39629_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/35106065","volume":"1","author":"M Malumbres","year":"2001","unstructured":"Malumbres, M. & Barbacid, M. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. Cancer. 1, 222\u2013231 (2001).","journal-title":"Nat. Rev. Cancer"},{"key":"39629_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","volume":"6","author":"CJ Sherr","year":"2016","unstructured":"Sherr, C. J., Beach, D. & Shapiro, G. I. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 6, 353\u2013367 (2016).","journal-title":"Cancer Discov"},{"key":"39629_CR16","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1158\/2159-8290.CD-16-0095","volume":"6","author":"A Patnaik","year":"2016","unstructured":"Patnaik, A. et al. Efficacy and safety of Abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast Cancer, Non-Small cell lung Cancer, and other solid tumors. Cancer Discov. 6, 740\u2013753 (2016).","journal-title":"Cancer Discov"},{"key":"39629_CR17","doi-asserted-by":"publisher","first-page":"608","DOI":"10.3389\/fonc.2018.00608","volume":"8","author":"F Schettini","year":"2018","unstructured":"Schettini, F. et al. CDK 4\/6 inhibitors as single agent in advanced solid tumors. Front. Oncol. 8, 608 (2018).","journal-title":"Front. Oncol."},{"key":"39629_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s11060-018-2977-3","volume":"140","author":"JW Taylor","year":"2018","unstructured":"Taylor, J. W. et al. Phase-2 trial of Palbociclib in adult patients with recurrent RB1-positive glioblastoma. J. Neurooncol.. 140, 477\u2013483 (2018).","journal-title":"J. Neurooncol"},{"key":"39629_CR19","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1124\/dmd.114.062745","volume":"43","author":"TJ Raub","year":"2015","unstructured":"Raub, T. J. et al. Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 Inhibition in combination with Temozolomide in an intracranial glioblastoma xenograft. Drug Metab. Dispos. 43, 1360\u20131371 (2015).","journal-title":"Drug Metab. Dispos."},{"key":"39629_CR20","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41568-022-00456-3","volume":"22","author":"S Goel","year":"2022","unstructured":"Goel, S., Bergholz, J. S. & Zhao, J. J. Targeting CDK4 and CDK6 in cancer. Nat. Rev. Cancer. 22, 356\u2013372 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"39629_CR21","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1073\/pnas.0909896107","volume":"107","author":"H Kim","year":"2010","unstructured":"Kim, H. et al. Integrative genome analysis reveals an oncomir\/oncogene cluster regulating glioblastoma survivorship. Proc. Natl. Acad. Sci. U S A. 107, 2183\u20132188 (2010).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"39629_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s11060-013-1179-2","volume":"114","author":"X Deng","year":"2013","unstructured":"Deng, X. et al. miR-124 radiosensitizes human glioma cells by targeting CDK4. J. Neurooncol.. 114, 263\u2013274 (2013).","journal-title":"J. Neurooncol"},{"key":"39629_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00401-018-1906-z","volume":"137","author":"GY L\u00f3pez","year":"2019","unstructured":"L\u00f3pez, G. Y. et al. The genetic landscape of gliomas arising after therapeutic radiation. Acta Neuropathol. 137, 139\u2013150 (2019).","journal-title":"Acta Neuropathol."},{"key":"39629_CR24","first-page":"867","volume":"40","author":"Z Dai","year":"2018","unstructured":"Dai, Z. et al. Oxymatrine induces cell cycle arrest and apoptosis and suppresses the invasion of human glioblastoma cells through the EGFR\/PI3K\/Akt\/mTOR signaling pathway and STAT3. Oncol. Rep. 40, 867\u2013876 (2018).","journal-title":"Oncol. Rep."},{"key":"39629_CR25","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-09-4559","volume":"70","author":"K Michaud","year":"2010","unstructured":"Michaud, K. et al. Pharmacologic Inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 70, 3228\u20133238 (2010).","journal-title":"Cancer Res."},{"key":"39629_CR26","doi-asserted-by":"publisher","first-page":"ii44","DOI":"10.1093\/neuonc\/noaa215.179","volume":"22","author":"P Wen","year":"2020","unstructured":"Wen, P. et al. CTNI-12. Preliminary results of the abemaciclib arm in the individualized screening trial of innovative glioblastoma therapy (INSIGHT): a phase II platform trial using bayesian adaptive randomization. Neuro. Oncol. 22, ii44\u2013ii44 (2020).","journal-title":"Neuro Oncol."},{"key":"39629_CR27","doi-asserted-by":"publisher","first-page":"e52176","DOI":"10.7554\/eLife.52176","volume":"9","author":"AR Pombo Antunes","year":"2020","unstructured":"Pombo Antunes, A. R. et al. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. Elife 9, e52176 (2020).","journal-title":"Elife"},{"key":"39629_CR28","doi-asserted-by":"publisher","first-page":"944455","DOI":"10.3389\/fphar.2022.944455","volume":"13","author":"H Li","year":"2022","unstructured":"Li, H. et al. Design, synthesis, and biological characterization of a potent STAT3 degrader for the treatment of gastric cancer. Front. Pharmacol. 13, 944455 (2022).","journal-title":"Front. Pharmacol."},{"key":"39629_CR29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/1471-2407-8-302","volume":"8","author":"JC Lieblein","year":"2008","unstructured":"Lieblein, J. C. et al. STAT3 can be activated through paracrine signaling in breast epithelial cells. BMC Cancer. 8, 302 (2008).","journal-title":"BMC Cancer"},{"key":"39629_CR30","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3390\/curroncol30020106","volume":"30","author":"N Brighi","year":"2023","unstructured":"Brighi, N. et al. Prospective evaluation of MGMT-Promoter methylation status and correlations with outcomes to Temozolomide-Based chemotherapy in Well-Differentiated neuroendocrine tumors. Curr. Oncol. 30, 1381\u20131394 (2023).","journal-title":"Curr. Oncol."},{"key":"39629_CR31","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.3390\/curroncol28040220","volume":"28","author":"T Mir","year":"2021","unstructured":"Mir, T., Pond, G. & Greenspoon, J. N. Outcomes in elderly patients with glioblastoma multiforme treated with Short-Course radiation alone compared to Short-Course radiation and concurrent and adjuvant Temozolomide based on performance status and extent of resection. Curr. Oncol. 28, 2399\u20132408 (2021).","journal-title":"Curr. Oncol."},{"key":"39629_CR32","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/cam4.3005","volume":"9","author":"YF Chen","year":"2020","unstructured":"Chen, Y. F. et al. TP3, an antimicrobial peptide, inhibits infiltration and motility of glioblastoma cells via modulating the tumor microenvironment. Cancer Med. 9, 3918\u20133931 (2020).","journal-title":"Cancer Med."},{"key":"39629_CR33","doi-asserted-by":"crossref","unstructured":"Pan, L., Chen, X., Rassool, F. V., Li, C. & Lin, J. LLL12B, a Novel Small-Molecule STAT3 Inhibitor, Induces Apoptosis and Suppresses Cell Migration and Tumor Growth in Triple-Negative Breast Cancer Cells. Biomedicines 10, (2022).","DOI":"10.3390\/biomedicines10082003"},{"key":"39629_CR34","doi-asserted-by":"crossref","unstructured":"Jalili-Nik, M. et al. Zerumbone Promotes Cytotoxicity in Human Malignant Glioblastoma Cells through Reactive Oxygen Species (ROS) Generation. Oxid. Med. Cell. Longev. 3237983 (2020).","DOI":"10.1155\/2020\/3237983"},{"key":"39629_CR35","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/cns.14024","volume":"29","author":"Y Miao","year":"2023","unstructured":"Miao, Y. et al. Anti-cancer effect of targeting fibroblast activation protein alpha in glioblastoma through remodeling macrophage phenotype and suppressing tumor progression. CNS Neurosci. Ther. 29, 878\u2013892 (2023).","journal-title":"CNS Neurosci. Ther."},{"key":"39629_CR36","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10495-020-01594-5","volume":"25","author":"SI Omoruyi","year":"2020","unstructured":"Omoruyi, S. I., Ekpo, O. E., Semenya, D. M., Jardine, A. & Prince, S. Exploitation of a novel phenothiazine derivative for its anti-cancer activities in malignant glioblastoma. Apoptosis 25, 261\u2013274 (2020).","journal-title":"Apoptosis"},{"key":"39629_CR37","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner, N. C. et al. Overall survival with Palbociclib and fulvestrant in advanced breast cancer. N. Engl. J. Med. 379, 1926\u20131936 (2018).","journal-title":"N Engl. J. Med."},{"key":"39629_CR38","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1158\/0008-5472.CAN-21-3656","volume":"82","author":"J Xiao","year":"2022","unstructured":"Xiao, J. et al. CDK4\/6 Inhibition enhances oncolytic virus efficacy by potentiating tumor-selective cell killing and T-cell activation in refractory glioblastoma. Cancer Res. 82, 3359\u20133374 (2022).","journal-title":"Cancer Res."},{"key":"39629_CR39","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/j.bmcl.2019.06.021","volume":"29","author":"SM Bronner","year":"2019","unstructured":"Bronner, S. M. et al. Design of a brain-penetrant CDK4\/6 inhibitor for glioblastoma. Bioorg. Med. Chem. Lett. 29, 2294\u20132301 (2019).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"39629_CR40","doi-asserted-by":"publisher","first-page":"W486","DOI":"10.1093\/nar\/gkr320","volume":"39","author":"TWH Backman","year":"2011","unstructured":"Backman, T. W. H., Cao, Y. & Girke, T. ChemMine tools: an online service for analyzing and clustering small molecules. Nucleic Acids Res. 39, W486\u2013W491 (2011).","journal-title":"Nucleic Acids Res."},{"key":"39629_CR41","doi-asserted-by":"publisher","first-page":"6893","DOI":"10.1007\/s12010-023-04441-w","volume":"195","author":"A Mishra","year":"2023","unstructured":"Mishra, A., Mulpuru, V. & Mishra, N. An interaction network driven approach for identifying Cervical, Endometrial, vulvar carcinomic biomarkers and their Multi-targeted inhibitory agents from few widely available medicinal plants. Appl. Biochem. Biotechnol. 195, 6893\u20136912 (2023).","journal-title":"Appl. Biochem. Biotechnol."},{"key":"39629_CR42","doi-asserted-by":"publisher","first-page":"9974","DOI":"10.1080\/07391102.2021.1938233","volume":"40","author":"S Akbar","year":"2022","unstructured":"Akbar, S., Das, S., Iqubal, A. & Ahmed, B. Synthesis, biological evaluation and molecular dynamics studies of oxadiazine derivatives as potential anti-hepatotoxic agents. J. Biomol. Struct. Dyn. 40, 9974\u20139991 (2022).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"39629_CR43","doi-asserted-by":"publisher","first-page":"e1000634","DOI":"10.1371\/journal.pcbi.1000634","volume":"6","author":"D Seeliger","year":"2010","unstructured":"Seeliger, D. & de Groot, B. L. Conformational transitions upon ligand binding: holo-structure prediction from Apo conformations. PLoS Comput. Biol. 6, e1000634 (2010).","journal-title":"PLoS Comput. Biol."},{"key":"39629_CR44","doi-asserted-by":"crossref","unstructured":"Rauf, A. et al. Aldose reductase inhibitory evaluation and in Silico studies of bioactive secondary metabolites isolated from Fernandoa. Adenophylla (Wall. Ex G. Don). J. Mol. Struct. 141308 (2025).","DOI":"10.1016\/j.molstruc.2024.141308"},{"key":"39629_CR45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1747-0285.2005.00323.x","volume":"67","author":"J Singh","year":"2006","unstructured":"Singh, J., Deng, Z., Narale, G. & Chuaqui, C. Structural interaction fingerprints: a new approach to organizing, mining, analyzing, and designing protein-small molecule complexes. Chem. Biol. Drug Des. 67, 5\u201312 (2006).","journal-title":"Chem. Biol. Drug Des."},{"key":"39629_CR46","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7, 42717 (2017).","journal-title":"Sci. Rep."},{"key":"39629_CR47","doi-asserted-by":"publisher","first-page":"27012","DOI":"10.1289\/EHP9341","volume":"130","author":"JVB Borba","year":"2022","unstructured":"Borba, J. V. B. et al. STopTox: an in Silico alternative to animal testing for acute systemic and topical toxicity. Environ. Health Perspect. 130, 27012 (2022).","journal-title":"Environ. Health Perspect."},{"key":"39629_CR48","doi-asserted-by":"publisher","first-page":"4370","DOI":"10.3390\/molecules27144370","volume":"27","author":"ED Raczy\u0144ska","year":"2022","unstructured":"Raczy\u0144ska, E. D. et al. Nitriles with high gas-phase basicity\u2014Part II transmission of the push\u2013pull effect through Methylenecyclopropene and Cyclopropenimine scaffolds intercalated between different electron donor (s) and the cyano N-protonation site. Molecules 27, 4370 (2022).","journal-title":"Molecules"},{"key":"39629_CR49","doi-asserted-by":"publisher","first-page":"174101","DOI":"10.1063\/1.3491272","volume":"133","author":"T Tsuneda","year":"2010","unstructured":"Tsuneda, T., Song, J. W., Suzuki, S. & Hirao, K. On koopmans\u2019 theorem in density functional theory. J. Chem. Phys. 133, 174101 (2010).","journal-title":"J. Chem. Phys."},{"key":"39629_CR50","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-025-02267-0","volume":"24","author":"A Pouyan","year":"2025","unstructured":"Pouyan, A. et al. Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. Mol. Cancer. 24, 58 (2025).","journal-title":"Mol. Cancer"},{"key":"39629_CR51","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.3390\/cimb46030153","volume":"46","author":"R Onciul","year":"2024","unstructured":"Onciul, R. et al. Deciphering glioblastoma: fundamental and novel insights into the biology and therapeutic strategies of gliomas. Curr. Issues Mol. Biol. 46, 2402\u20132443 (2024).","journal-title":"Curr. Issues Mol. Biol."},{"key":"39629_CR52","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s12935-024-03331-3","volume":"24","author":"H Ghaznavi","year":"2024","unstructured":"Ghaznavi, H. et al. New insights into targeted therapy of glioblastoma using smart nanoparticles. Cancer Cell. Int. 24, 160 (2024).","journal-title":"Cancer Cell. Int."},{"key":"39629_CR53","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41698-024-00653-3","volume":"8","author":"T Freitag","year":"2024","unstructured":"Freitag, T. et al. Combined Inhibition of EZH2 and CDK4\/6 perturbs Endoplasmic reticulum-mitochondrial homeostasis and increases antitumor activity against glioblastoma. NPJ Precis Oncol. 8, 156 (2024).","journal-title":"NPJ Precis Oncol."},{"key":"39629_CR54","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13568-024-01742-z","volume":"14","author":"A Akram","year":"2024","unstructured":"Akram, A. et al. Silibinins and Curcumin as promising ligands against mutant cystic fibrosis transmembrane regulator protein. AMB Express. 14, 84 (2024).","journal-title":"AMB Express"},{"key":"39629_CR55","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1002\/cmdc.201700449","volume":"12","author":"H Abdelkarim","year":"2017","unstructured":"Abdelkarim, H. et al. Design, Synthesis, molecular Modeling, and biological evaluation of novel Amine-based histone deacetylase inhibitors. ChemMedChem 12, 2030\u20132043 (2017).","journal-title":"ChemMedChem"},{"key":"39629_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-025-99215-1","volume":"15","author":"A Alanazi","year":"2025","unstructured":"Alanazi, A. et al. A combined in Silico and MD simulation approach to discover novel LpxC inhibitors targeting multiple drug resistant Pseudomonas aeruginosa. Sci. Rep. 15, 1\u201319 (2025).","journal-title":"Sci. Rep."},{"key":"39629_CR57","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1080\/07391102.2023.2300121","volume":"43","author":"M Khan","year":"2025","unstructured":"Khan, M. et al. Computational exploration of allosteric inhibitors targeting CDK4\/CDK6 proteins: a promising approach for multi-target drug development. J. Biomol. Struct. Dyn. 43, 3783\u20133801 (2025).","journal-title":"J. Biomol. Struct. Dyn."},{"key":"39629_CR58","doi-asserted-by":"crossref","unstructured":"Rauf, A. et al. Anticancer potential of flavonoids isolated from pistacia chinensis against glioblastoma (U87) cell line: extensive in vitro and in Silico research. Eurasian J. Med. Oncol. 5768 (2025).","DOI":"10.36922\/ejmo.5768"},{"key":"39629_CR59","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv Rev. 46, 3\u201326 (2001).","journal-title":"Adv. Drug Deliv Rev."},{"key":"39629_CR60","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12989-022-00489-4","volume":"19","author":"WC Chou","year":"2022","unstructured":"Chou, W. C. et al. Development of a multi-route physiologically based Pharmacokinetic (PBPK) model for nanomaterials: a comparison between a traditional versus a new route-specific approach using gold nanoparticles in rats. Part. Fibre Toxicol. 19, 47 (2022).","journal-title":"Part. Fibre Toxicol."},{"issue":"43","key":"39629_CR61","doi-asserted-by":"publisher","first-page":"e202404283","DOI":"10.1002\/slct.202404283","volume":"9","author":"A Guendouzi","year":"2024","unstructured":"Guendouzi, A. et al. Unveiling novel hybrids Quinazoline\/Phenylsulfonylfuroxan derivatives with potent Multi-Anticancer inhibition: DFT and in Silico approach combining 2D\u2010QSAR, molecular Docking, dynamics Simulations, and ADMET properties. ChemistrySelect 9 (43), e202404283 (2024).","journal-title":"ChemistrySelect"},{"key":"39629_CR62","doi-asserted-by":"publisher","first-page":"7749","DOI":"10.1038\/s41598-024-58485-x","volume":"14","author":"F Zare","year":"2024","unstructured":"Zare, F. et al. A combination of virtual screening, molecular dynamics simulation, MM\/PBSA, ADMET, and DFT calculations to identify a potential DPP4 inhibitor. Sci. Rep. 14, 7749 (2024).","journal-title":"Sci. Rep."},{"key":"39629_CR63","doi-asserted-by":"publisher","first-page":"100457","DOI":"10.1016\/j.jgeb.2025.100457","volume":"23","author":"SK Mishra","year":"2025","unstructured":"Mishra, S. K. et al. Unveiling the molecular activity of HIV towards the CD4: A study based on subtype C via Docking and dynamics approach. J. Genet. Eng. Biotechnol. 23, 100457 (2025).","journal-title":"J. Genet. Eng. Biotechnol."},{"issue":"1","key":"39629_CR64","doi-asserted-by":"publisher","first-page":"33787","DOI":"10.1038\/s41598-025-01232-7","volume":"15","author":"H Manzoor","year":"2025","unstructured":"Manzoor, H. et al. Computational identification and evaluation of novel PD-L1 inhibitors for cancer immunotherapy. Sci. Rep. 15 (1), 33787 (2025).","journal-title":"Sci. Rep."},{"issue":"1","key":"39629_CR65","doi-asserted-by":"publisher","first-page":"34076","DOI":"10.1038\/s41598-025-14557-0","volume":"15","author":"H Manzoor","year":"2025","unstructured":"Manzoor, H. et al. Citronellol silver nanoconjugates as a therapeutic strategy for glioblastoma through computational and experimental evaluation. Sci. Rep. 15 (1), 34076 (2025).","journal-title":"Sci. Rep."},{"issue":"6","key":"39629_CR66","doi-asserted-by":"publisher","first-page":"e0325281","DOI":"10.1371\/journal.pone.0325281","volume":"20","author":"H Manzoor","year":"2025","unstructured":"Manzoor, H. et al. Linalool-based silver nanoconjugates as potential therapeutics for glioblastoma: in Silico and in vitro insights. PLOS ONE. 20 (6), e0325281 (2025).","journal-title":"PLOS ONE"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39629-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39629-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39629-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:02:09Z","timestamp":1773669729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-39629-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["39629"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-39629-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9000"}}